Skip to content

Daily News
Quiz
Login

Daily News
Quiz
Login

News

Risankizumab Under Review for Moderately to Severely Active Ulcerative Colitis

July 20, 2024

An Educational Initiative by

The makers of

Disclaimer: The information is provided for general informational and educational purposes only. The content is developed by MedX Scientific Healthcare for creating awareness and not intended for commercial use. This scientific, educational initiative is supported by IPCA as an unrestricted educational grant. IPCA disclaims any liability arising out of reliance on this content.

Scroll to Top